It is known that aspartic acid isomerization process plays a role in aging processes and may be used as a marker for aging of natural materials. As for Alzheimer's disease, the most abundant modification in the peptide profile is the aspartate isomerization of amyloid-b. Liquid chromatography-electrospray ionization-mass spectrometry/mass spectrometry-based approaches with Collision Induced Dissociation (CID) or Electron Capture Dissociation (ECD) fragmentation provide a good and precise method for the relative quantitation of iso-to normal amyloid-b peptides but require additional time consuming steps. In this study, MALDI-TOF/TOF-matrix-assisted laser desorption ionization time-of-flight tandem mass spectrometry (MS) method was developed as a high-throughput approach for the relative quantitation of the isomerized form of the amyloid-b peptide.
Introduction
Liquid chromatography followed by electrospray ionization (ESI) is the gold standard for mass spectrometry (MS) quantification of various classes of chemical compounds. Nevertheless, advantages of MALDI-TOF-MS such as speed, sensitivity, and low sample consumption are widely used for quality control during sample preparation and qualitative analysis rather than quantitation. 1, 2 It is supposed that disadvantages of MALDI techniques especially the problems of cocrystallization of analytes and internal standards with matrix leading to unevenness of their signal could be a problem for proper quantitation 3 but this problem should not be significant in case of peptide isomers 1, 4 because of the similarity of their physical properties. In this case, such method could be applied for relative quantitation of normal and isomerized forms of peptides in mixtures. Isomerization of a-aspartic acid, which leads to the formation of a b-amino acid through a succinimide intermediate, is a well-known peptide modification. 5, 6 Isoaspartate-containing proteins play a significant role in aging processes and may lose their structure and become biologically inactive or even harmful. One such peptide is the amyloid-b, which is a normal blood component present in the bloodstream of healthy individuals, as well as patients with Alzheimer's disease. 7 This disease is characterized by a severe accumulation of proteinaceous plaques in the brain tissues of elderly people. These plaques are mostly composed of aggregated amyloid-b peptides with a high level of b-Asp residues, so the percentage of isomerized forms of peptides could possibly be used as a diagnostic criterion of Alzheimer's disease. The difficulty of relative quantitation of amyloid-b peptides consists in the low concentration of them in plasma or small amount of sample in case of brain extracts. Also, it is not possible to distinguish the normal and iso-form of molecules using MS because of the identity in their molecular masses. But distinctions in spectra between normal and b-aspartic acid-containing peptides could be detected using MS/MS techniques, and previously, it has been shown that ESI-based MS with CID or ECD fragmentation provides a good and precise method for the relative quantitation of iso-to normal amyloid-b peptides but of limited sensitivity and requiring additional time-consuming steps such as long sample preparation and chromatography for sample concentration. 8, 9 For this reason, a MALDI-TOF/TOF-MS method was developed for relative quantitation of the isomerized form of the amyloid-b peptide.
Method
To determine the differences between normal and bAsp7 isoforms of the amyloid-b peptide in MS/MS spectra, experiments with model systems were carried out. Synthetic amyloid-b 1-16 and 1-42 peptides (BioPeptide Inc.), with both normal and b-Asp7, were analyzed individually and in binary mixtures. All experiments were performed on a Bruker ultrafleXtreme MALDI-TOF/TOF instrument using (alpha-cyano-4-hydroxycinnamic acid (HCCA) for 1-16 peptides) and (2,5-dihydroxybenzoic acid (DHB) for 1-42 peptides) matrices. Fragmentation spectra were obtained using the laser ionization fragmentation technology (LIFT) technique in CID mode with ultrahigh purity helium, nitrogen, and argon as collision gases. LIFT-fragmentation without collision gas yielded low intensity and low variability of fragments, while all tested collision gases allowed to obtain intensive fragment-rich spectra. For each of the MS/MS spectra, marker and base ions were chosen. Base ions were determined as ions whose intensity does not depend on the form of the peptide and are mostly formed from the dissociation of bonds far away from the 7th amino acid. Marker ions are those ions whose intensity significantly changes depending on the form of the peptide and are usually obtained by dissociation of bonds near the aspartate residue.
Results and discussion
Unlike ECD, 8, 10 fragmentation dissociation of the C-C bond in the middle of isoaspartic acid which results in the formation of ions c 6 þ57 þ and z 10 -57 þ is not observed, so only changes in the relative intensities of c 6 þ57 þ and z 10 -57 þ to base ions could be used for peptide isoform determination. 11 Fragmentation spectra obtained with different collision gases are different from each other, and even though marker ions obtained with all of them are almost the same, their intensities relative to base ions vary significantly possibly due to different mass-to-size ratio of different gases that changes the probability and energy of collisions. The use of argon as the collision gas produces spectra with the highest intensities of marker ions, so it was used for determination of the detection limit of the developed method. Marker ions are shown in Table 1 . The most notable difference in the fragmentation spectra of the amyloid-b 1-16 with a normal and isomerized aspartate 7 residue is in the formation of predominantly the c 6 þ (m/z 773.37 Da) fragment for the normal peptide and the b 6 þH 2 O þ (m/z 774.33 Da) fragment for the b-Asp7 isoform (Figure 1 ), which are formed through OH migration from aspartic acid's free carboxyl group to c-terminus of forming b6 fragment during peptide bond dissociation. 11, 12 Unfortunately, due to their mass difference, the overlap in their isotopic distributions prevents direct comparison of their intensities, and the contribution of each ion in the intensity of every detected peak needs to be considered. The contribution to (Mþ1) þ and (Mþ2) þ ions can be predicted since in these peptide fragments only the C 13 isotope could give a notable contribution to the spectra. Thus, the real intensity of the b 6 þH 2 O þ ion can be calculated by subtracting the contribution of the c 6 þ ion (773.37 m/z intensity signal multiplied by the isotopic distribution coefficient 42.46%) from the measured intensity of the 774.33 m/z signal. In order to check the calculations, the sum of the c 6 þ2
þ and the b 6 þH 2 Oþ1 þ contributions was compared to the measured 775.33 m/z signal, and an error of less than 5% was observed in each experiment. The change in the intensity ratios of the b 6 þH 2 O þ to base ions (referred to normal peptide) was 18.2, 17, and 16.1 fold for He, N 2 , and Ar, respectively. The direct ratio of the c 6 þ to b 6 þH 2 O þ changed by 10.7, 9.9, and 10.1 folds, respectively. For the 1-42 peptides, the overall intensities and signal-tonoise ratios were considerably lower than those for the 1-16 peptides, so much a higher detection limit and lower selectivity were observed. Nevertheless, this method can also be applied for the 1-42 fragment of amyloid-b, which due to its high aggregation ability is difficult to analyze by ESI-MS. Since MALDI-TOF measurements allow to use small amounts of sample or less concentrated samples without additional sample preparation steps, amounts of less than 1 ng of peptide could be reliably detected, and this value could be improved by concentrating the sample directly on the target plate. This simple method could also be adapted to other peptides and proteins prone to aspartic acid isomerization, so relative quantitation of isoforms of molecules could be rapidly performed with MALDI-TOF/TOF instruments.
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